Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

MUSCLE & NERVE is a prestigious journal dedicated to the exploration and advancement of knowledge in the fields of neurology, cellular and molecular neuroscience, and physiology. Published by Wiley, this journal has been a crucial resource for researchers and practitioners since its inception in 1978, with an impressive convergence of studies anticipated through 2024. With an Impact Factor reflecting its relevance and influence—ranking in the Q2 and Q3 quartiles across multiple categories, including clinical neurology and medical physiology—MUSCLE & NERVE offers a rigorous peer-reviewed platform for groundbreaking research. It holds a respected position in Scopus rankings, illustrating its commitment to excellence and innovation in medicine and neuroscience. As a non-open access journal, it provides valuable resources for professionals seeking to further their understanding of neuromuscular physiology and related disciplines. The journal aims to foster dialogue and disseminate knowledge that advances the field, making it an indispensable tool for academics and clinicians alike.

The INTERNATIONAL JOURNAL OF NEUROSCIENCE, published by TAYLOR & FRANCIS LTD, stands as a vital resource in the field of neuroscience since its inception. With a proud history of publication from 1970 to 2024, this journal is committed to advancing knowledge in various domains of neuroscience, from fundamental research to clinical applications. It is indexed with an ISSN of 0020-7454 and an E-ISSN of 1563-5279, reflecting its wide reach and recognition. The journal maintains a respectable position in the academic landscape, categorized as Q2 in Medicine (miscellaneous) and Q3 in Neuroscience (miscellaneous) as of 2023, signifying its relevance among researchers and professionals. Although it currently does not offer open access, the journal remains a significant platform for disseminating groundbreaking research, thereby fostering collaboration and innovation within the neuroscience community. Located in the United Kingdom, the journal aims to bridge gaps in neuroscience knowledge, making it an essential reading for students, professionals, and researchers dedicated to unraveling the complexities of the nervous system.

NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.

NEUROGENETICS is a distinguished journal published by SPRINGER, focusing on the intersection of genetics and neuroscience. With its ISSN 1364-6745 and E-ISSN 1364-6753, this journal has been a vital resource in the fields of cellular and molecular neuroscience and genetics since its establishment in 1997. As of 2023, it is ranked Q3 in Cellular and Molecular Neuroscience and Q2 in both Genetics and Clinical Genetics, reflecting its growing influence and importance in these areas. Although not an open-access journal, it provides significant insights and research findings that contribute to advancing our understanding of genetic influences on neural function and disease. Based in Germany with an address at ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES, NEUROGENETICS serves as a crucial platform for researchers, professionals, and students alike to explore innovative studies that are essential for the future of neuroscience and genetics. With its continuous commitment to high-quality research, the journal aims to foster collaboration and knowledge dissemination among the scientific community.

Journal of Neuromuscular Diseases, published by IOS PRESS, is a leading platform dedicated to advancing the field of neurology and neuromuscular research. With a focus on delivering high-quality, peer-reviewed content, this journal aims to foster knowledge sharing and collaboration among researchers, clinicians, and healthcare professionals dealing with neuromuscular disorders. The journal boasts a commendable impact factor within its respective categories, achieving Q2 rankings in both Neurology and Clinical Neurology as of 2023. Spanning from its inception in 2014 to the anticipated convergence in 2024, it is recognized for its contributions to critical discussions in the field, evidenced by its rankings of #145 out of 400 in clinical neurology and #75 out of 192 in neuroscience. As an open access journal, it facilitates wider accessibility of research findings, catering to an audience eager for innovative approaches and developments. Set against the backdrop of the vibrant academic scene in the Netherlands, the Journal of Neuromuscular Diseases serves as an essential resource for driving forward the boundaries of knowledge in neuromuscular-related conditions.

Nature Reviews Neurology, published by NATURE PORTFOLIO, stands as a leading scholarly journal dedicated to the field of neurology and neuroscience. With an impressive impact factor and a prestigious Q1 categorization in both Cellular and Molecular Neuroscience and Clinical Neurology, this journal provides cutting-edge reviews and insights into the latest research developments, trends, and clinical practices. Based in the United Kingdom and accessible to a global audience, Nature Reviews Neurology aims to foster knowledge dissemination and interdisciplinary collaboration among researchers, healthcare professionals, and educators. With an influential Scopus ranking, it remains a pivotal resource for those seeking to deepen their understanding of neurological disorders and therapies while remaining at the forefront of academic discourse and innovation in the field.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.